2. Insurance premium grew by 68% YoY to ₹ 1,796 Cr.
3. Credit disbursals grew by 94% to ₹ 1,926 Cr.
4. Adjusted EBITDA for Q3 was a loss of ₹ 92
5. Existing business contribution margin was maintained at 40%
For 9M FY22 Revenues grew by 44% to ₹ 950 Cr including additional deferred revenue of 75 Cr which will be received in next 12 months.
6. Adjusted EBITDA for 9M FY22 was a loss of ₹ 203 Cr.
7. For 9M FY22 Insurance premium grew by 38% YoY to ₹ 4,812 Cr and Credit disbursals grew by 169% to ₹ 4,416 Cr.
8. ESOP charges were ₹236 Cr for the quarter.
Business Update
1. PB Partners (PoSP business) became the #1 B2B2C platform in the country within its six month of launch.
2. PB UAE business is now a #2 in a fast growing market.
3. PB Corporate now covers 1.1Mn customers and is the fastest growing corporate/SME insurance business in India.
4. Company has invested approximately ₹200 Crores in their brand and these new initiatives which they believe will be value accretive in coming years.
5. Insurance premium with annualized run rate (ARR) of ₹ 8,108 Crores is growing 60% YoY.
6. Total customers using the credit score platform crossed 26Mn in the month of January 2022.
7. Paisabazaar after COVID is now over ₹ 8,400 Crores ARR.
With PB partners the company will see expansion in their customers.
8. For last quarter renewal business was ₹55 cr. renewal business numbers are growing at 40% YoY and majority of the renewals come from the health insurance side with more than 90% margins.
9. Company’s has an offline strategy where now more than 300 agents are deployed and these agents can go to their customer homes in order to fulfil the order which was placed on policybazaar.
It can be health insurance, motor insurance etc.
10. The offline fulfilment counts for 3% of the total revenue.
11. On increase in employee expense management says this increase is because this year they have invested in building a team for their long term strategy.
12. On LIC partnership, company says they will go step by step with their goal, being complementary at start by offering products like fixed return plans and Ulips.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY
2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore
3. Gross margins in 9M FY22 stood at 41.4%
4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.
3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.